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POEMS
Local radiation therapy was administered in two patients for sclerotic lesions.
Minimal or no clinical improvements were observed in response to these therapies after a median follow-up of 4 (1-36) months.
All but three patients received salvage treatment with the combination of lenalidomide 25mg/day for 21 days in 28-day cycles with dexamethasone (40mg/week). Two patients (case 3 and 10) received the prior scheme with a lower dose of lenalidomide (15mg/day) and another patient was treated with lenalidomide alone at 25mg/day (case 8). Median number of lenalidomide courses was 7.5 (6-18), with four patients receiving 6 cycles, two 8 cycles, and the remaining four cases received 7, 12, 13 and 18 cycles. All patients improved after lenalidomide treatment, even those that underwent an SCT later, ( Table   2 ). Due to a delayed responses observed with treatments like melphalan some effect of the previous treatment could contribute to the responses observed as could occurred in cases 3,4 and 5. Clinical resolution of neuropathy was observed in four cases and in the remaining patients a significantly improvement in neurological symptoms was noted. None of the patients confined to a wheelchair needed it anymore and all but three recover a fully independent walk (these patients needed support with crutches or assistance).
With respect to the M-component a negative immunofixation was reached in five patients. [5] [6] [7] [8] [9] [10] [11] . Dispenzieri and collaborators were the first to suggest the efficacy of the lenalidomide and dexamethasone combination for POEMS syndrome, since its administration led to a marked improvement of a patient with POEMS syndrome, especially at the neurological level, with the recovery of the ability to walk; moreover, improvements in the functional status, VEGF and IL-6 levels, skin changes and anasarca were also observed 5 . Similarly, another patient was able to walk further and climb stairs without assistance after 4 cycles of this therapy 9 . Also, an unusual case of POEMS syndrome with Kappa restriction showed improved symptoms and the resolution of the associated neuropathy 6 after lenalidomide treatment.
These facts coincide with the favorable outcomes shown in the 10 patients described here, who, after receiving lenalidomide, experienced an improvement in their systemic manifestations, especially of the polyneuropathic condition. All patients improved extremity mobility and strength, and patients confined to wheelchair or bed-bound (7) regained the ability to walk. This is one of the most relevant advances in terms of the quality of life of the patients, since one of the main characteristics of this syndrome is the compromise of peripheral nerves. In addition, other improvements included disappearance or decrease in The favorable responses shown in the 10 cases presented in this article make it evident the efficacy of lenalidomide in the recovery from neurological damage associated with POEMS syndrome, both at the sensory and motor levels, which is one of the more devastating manifestations of the progression of this disease.
Therefore, these observations support the use of this immunomodulatory agent in patients with POEMS syndrome. The treatment-related adverse events associated with lenalidomide, reported for two of the patients, were largely predictable and manageable.
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